Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*

2004919 citationsJournal Article

Authors

In this study, the nonselective nitric oxide synthase inhibitor 546C88 increased mortality in patients with septic shock.

Good health and well-being

Published in: Critical Care Medicine

Volume 32, Issue 1, pp. 21-30

Field-Weighted Citation Impact: 30.72